Homocysteine, folic acid, group B vitamins and cardiovascular risk;Homocystéine, acide folique, vitamines du groupe B et risque cardiovasculaire

Archives des Maladies du Coeur et des Vaisseaux

Volumn 98, Issue 2, 2005, Pages 145-152

  Blacher, J ^a   Czernichow, S ^a   Horrellou, M H ^a   Conard, J ^a   David, P ^a   Chadefaux Vekemans, B ^b   Ankri, A ^c   Galan, P ^d   Hercberg, S ^d   Ducimetiere P ^e  

^a HÔTEL DIEU   (France)

^b Service de Biochemie B Necker

^c Service d'Hématologie Biologique   (France)

^d INSERM   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; HOMOCYSTEINE; VITAMIN B GROUP; ANTIANEMIC AGENT; VITAMIN B COMPLEX;

AMINO ACID BLOOD LEVEL; CARDIOVASCULAR RISK; CONGENITAL BLOOD VESSEL MALFORMATION; HUMAN; HYPERHOMOCYSTEINEMIA; REVIEW; THROMBOSIS; BLOOD; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; RISK FACTOR;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS; FOLIC ACID; HEMATINICS; HUMANS; HYPERHOMOCYSTEINEMIA; RISK FACTORS; VITAMIN B COMPLEX;

EID: 18344377526     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Hill AB. A short textbook of medical statistics. London : Hodder and Stoughton, 1977 ; 24 : 285-96.
2. Montalescot G. Homocysteine: the new player in the field of coronary risk. Heart. 1996 ; 76 : 101-2.
3. Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds). The metabolic basis of inherited disease, 8th ed. New York : Mc Graw-Hill, 2001 ; 28 : 2007-56.
4. Hajjar KA. Homocysteine: a sulph'rous fire. J Clin Invest 2001 ; 107 : 663-4.
5. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995 ; 274 : 1074-57.
6. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements meta-analysis of randomised trials. BMJ 1998 ; 316 : 894-8.
7. Carson NAJ, Neill DW. Metabolic abnormalities detected in a survey of mentally backward individuals in Northen Ireland. Arch Dis Child 1962 ; 37 : 505-13.
8. Mudd SH, Skovby F, Levy HL et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 1985 ; 37 : 1-31.
9. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arterosclerosis. Am J Pathol 1969 ; 56 : 111-2.
10. Wilcken DEL, Wilcken B. The pathogenesis of coronary artery disease: a possible role for methionine metabolism. J Clin Invest 1976 ; 57 : 1079-82.
11. Tsai JC, Perrela MA, Yoshizumi M et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Nat Acad Sci USA 1994 ; 91 : 6369-73.
12. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocysteinemia is associated with impaired endothelium-dependent vasodilatation in humans. Circulation 1997 ; 95 : 1119-21.
13. Charpiot P, Bescond A, Augier T et al. Hyperhomocysteinemia induces elastolysis in minipig arteries: structural consequences, arterial site specificity and effect of captopril-hydrochlorothiazide. Matrix Biol 1998 ; 17 : 559-74.
14. Loscalzo J. The oxidant stress of hyperhomocysteinemia. J Clin Invest 1996 ; 98 : 5-7.
15. Hofmann MA, Lalla E, Lu Y et al. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest 2001 ; 107 : 675-83.
16. Majors A, Ehrhart LA, Pezacka EH. Homocysteine as a risk factor for vascular disease. Arterioscler Thromb Vasc Biol 1997 ; 17 : 2074-81.
17. Malinow MR, Bostom AG, Krauss RM. Homocysteine, diet and cardiovascular diseases. A statement for healthcare professionals from the nutrition committee, American Heart Association. Circulation 1999 ; 99 : 178-82.
18. Christen WG, Ajani UA, Glynn RJ, Hennekens CH. Blood levels of homocysteine and increased risks of cardiovascular disease. Causal or casual? Arch Intern Med 2000 ; 160 : 422-34.
19. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997 ; 337 : 230-6.
20. Bostom AG, Shemin D, Verhoef P et al. Elevated fasting plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioscler Thromb Vasc Biol 1997 ; 17 : 2554-8.
21. Moustapha A, Naso A, Nahlawi M et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998 ; 97 : 138-41.
22. Ducloux D, Motte G, Challier B, Gibey R, Chalopin JM. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. J Am Soc Nephrol 2000 ; 11 : 134-7.
23. Taylor LM, De Franq RD, Harris FJ, Porter JM. The association of elevated plasma homocysteine with progression of symptomatic peripheral arterial disease. J Vasc Surg 1991 ; 13 : 128-36.
24. Taylor LM, Moneta GL, Sexton GJ, Schuff RA, Porter JM. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J Vasc Surg 1999 ; 29 : 8-19.
25. Stampfer MJ, Malinow MR, Willett WC et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992 ; 268 : 877-81.
26. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995 ; 24 : 704-9.
27. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995 ; 346 : 1395-8.
28. Wald NJ, Watt HC, law MR, Weir DG, McPartlin J, Scott JM. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med 1998 ; 158 : 862-7.
29. Stehouwer CD, Weijenberg MP, van den Berg M, Jakobs C, Feskens FJ, Kromhout D. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: a 10-year follow-up. Arterioscler Thromb Vasc Biol 1998 ; 18 : 1895-901.
30. Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996 ; 348 : 1120-4.
31. Bots ML, Launer LJ, Lindemans J et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam study. Arch Intern Med 1999 ; 159 : 38-44.
32. Bostom AG, Rosenberg IH, Silbershatz H et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham study. Ann Intern Med 1999 ; 131 : 352-5.
33. Bostom AG, Silbershatz H, Rosenberg IH et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med 1999 ; 159 : 1077-80.
34. Kark JD, Selhub J, Adler B et al. Nonfasting plasma total homocysteine level and mortality in middle-aged and elderly men and women in Jerusalem. Ann Intern Med 1999 ; 131 : 321-30.
35. Whincup PH, Refsum H, Perry IJ et al. Serum total homocysteine and coronary heart disease: prospective study in middle aged men. Heart 1999 ; 82 : 448-54.
36. Ridker PM, Manson JE, Buring JE, Shih J, Matias M, Hennekens CH. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA 1999 ; 281 : 1817-21.
37. Stehouwer CDA, Gall MA, Hougaard P, Jakobs C, Parving HH. Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminuria. Kidney Int 1999 ; 55 : 308-14.
38. Hoogeveen EK, Kostense PJ, Jakobs C et al. Hyperhomocysteinemia increases the risk of death, especially in type 2 diabetes. 5-year follow-up of the Hoorn study. Circulation 2000 ; 101 : 1506-11.
39. Aronow WS, Ahn C, Gutstein H. Increased plasma homocysteine is an independent predictor of new atherothrombotic brain infarction in older persons. Am J Cardiol 2000 ; 86 : 585-6.
40. Omland T, Samuelsson A, Hartford M et al. Serum homocysteine concentration as an indicator of survival in patients with acute coronary syndromes. Arch Intern Med 2000 ; 160 : 1834-40.
41. Stubbs PJ, Al-Obaidi MK, Conroy RM, Collinson PO, Graham IA, Noble MIM. Effect of plasma homocysteine concentration on early and late events in patients with acute coronary syndromes. Circulation 2000 ; 102 : 605-10.
42. Anderson JL, Muhlestein JB, Horne BD et al. Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation 2000 ; 102 : 1227-32.
43. Knekt P, Alfthan G, Aromaa A et al. Homocysteine and major coronary events: a prospective population study amongst women J Intern Med 2001 ; 249 : 461-5.
44. Vollset SE, Refsum H, Tverdal A et al. Plasma total homocysteine and cardiovascular and non cardiovascular mortality: the Hordaland homocysteine study. Am J Clin Nutr 2001 ; 74 : 130-6.
45. Blacher J, Benetos A, Kirzin JM, Malmejak A, Guize L, Safar M. Relation of plasma total homocysteine to cardiovascular mortality in a French population. Am J Cardiol 2002 ; 90 : 591-595.
46. Zylberstein DE, Bengtsson C, Björkelund C et al. Serum homocysteine in relation to mortality and morbidity from coronary heart disease. A 24-year follow-up of the population study of women in Gothenburg. Circulation 2004 ; 109 : 601-6.
47. Knekt P, Reunanen A, Alfthan G et al. Hyperhomocysteinemia. A risk factor or a consequence of coronary heart disease ? Arch Intern Med 2001 ; 161 : 1589-94.
48. Verhoel P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke 1994 ; 25 : 1924-30.
49. Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller LH, for the MRFIT Research Group. Homocysteine and risk of cardiovascular disease in the multiple risk factor intervention trial. Arterioscler Thromb Vasc Biol 1997 ; 17 : 1947-53.
50. Folsom AR, Nieto J, Mc Govern PG et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins. The atherosclerosis risk in communities (ARIC) study. Circulation 1998 ; 98 : 204-10.
51. Chasan-Taber L, Selhub J, Rosenberg IH et al. A prospective study of folate and vitamine B6 and risk of myocardial infarction in US physicians. J Am Coll Nutr 1996 ; 15 : 136-43.
52. Verhoel P, Hennekens CH, Allen RH, Stabler SP, Willett WC, Stampfer MJ. Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery. Am J Cardiol 1997 ; 79 : 799-801.
53. Alfthan G, Pekkanen J, Jauhiainen M et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994 ; 106 : 9-19.
54. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Enql J Med 2000 ; 342 : 836-43.
55. Suliman ME, Qureshi AR, Barony P et al. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int 2000 ; 57 : 1727-35.
56. Voutilainen S, Lakka TA, Hamelahti P, Lehtimaki T, Poulsen HE, Salonen JT. Plasma total homocysteine concentration and the risk of acute coronary events: the Kuopio ischemic heart disease risk factor study. J Intern Med 2000 ; 248 : 217-22.
57. Ridker, PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis. A comparison of C-Reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001 ; 285 : 2481-5.
58. de Bree A, Verschuren WM, Blom HJ et al. Coronary heart disease, mortality, plasma homocysteine, and B-vitamins: a prospective study. Atherosclerosis 2003 ; 166 : 369-77.
59. Clarke R, Shipley M, Lewington S et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 1999 ; 150 : 341-53.
60. Meigs JB, Jacques PF, Selhub J et al. Fasting plasma homocysteine levels in the insulin resistance syndrome. The Framingham Offspring Study. Diabetes Care 2001 ; 24 : 1403-10.
61. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: 6 000 events in 30 observational studies. JAMA 2002 ; 288 : 2015-22.
62. Omenn GS. Interpretations of the Linxian vitamin supplement chemoprevention trials. Epidemiology 1998 ; 9 : 1-4.
63. Peterson JC, Spence JD. Vitamins and progression of atherosclerosis in hyperhomocysteinaemia. Lancet 1998 ; 351 : 263.
64. Vermeulen EGJ, Stehouwer CDA, Twisk JWR et al. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet 2000 ; 355 : 517-22.
65. Wilcken DEL, Wilcken B. The natural history of vascular disease in homocystinuria 66. Title LM, Cummings PM, Giddens K, Genest JJJr, Nassar BA. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. J Am Coll Cardiol 2000 ; 36 : 758-65.
66. Chambers JC, Ueland PM, Obeid OA, Wrigley J, Refsum H, Kooner JS. Improved vascular endothelial function after oral B vitamins. An effect mediated through reduced concentrations of free plasma homocysteine. Circulation 2000 ; 102 : 2479-83.
67. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Effect of homocystein-lowering therapy with folic acid, vitamin B12 and vitamin B6, on clinical outcome after percutaneous coronary intervention. The Swiss Heart Study: a randomized controlled trial. JAMA 2002 ; 288 : 973-9.
68. Toole JF, Malinow MR, Chambless LE et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction and death. The Vitamin intervention for Stroke Prevention (VISP) randomised controlled trial. JAMA 2004 ; 291 : 565-75.
69. Galan P, de Bree A, Mennen L et al. Background and rationale of the SU.FOL.OM3 study: double-blind randomized placebo-controlled secondary prevention trial to test the impact of supplementation with folate, vitamin B6 and B12 and/or omega-3 fatty acids on the prevention of recurrent ischemic events in subjects with atherosclerosis in the coronary or cerebral arteries. J Nutr Health Aging 2003 ; 7 : 428-35.
70. Savage DG, Lindenbaum J. Folate-cobalamine interactions. In: Bailey LB (ed). Folate in Health and Disease. New York, NY: Marcel Dekker Inc. 1995 : 237-85.
71. Butterworth CE, Tamura T. Folic acid safely and toxicity: a brief reiew. Am J Clin Nutr 1989 ; 50 : 353-9.
72. Linder MC. Nutrition and metabolism of vitamins. In: Linder MC, ed. Nutritional Biochemistry and Metabolism with Clinical Applications. New York : Elsevier 1985; p 69.
73. Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases. A statement for healthcare professionals from the nutrition committee, American Heart Association. Circulation 1999 ; 99 : 178-82.
74. CAST Investigators. Effects of encainide and flecainide on mortality in randomized trial or arythmia suppression after myocardial infarction. N Engl J Med 1989 ; 321 : 406-12.
75. Chobanian AV, Bakris GL, Black HR et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003 ; 289 : 2560-72.